VolitionRx : Corporate Presentation February 2023

Corporate Deck

February 2023

Property of Volition© 2023

Slide 1

Forward Looking Statements and Disclaimer

Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as

"expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the timing, completion and delivery of data from clinical studies, the effectiveness of Volition's blood-based diagnostic and prognostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic or prognostic tool for COVID-19. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its

tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of

operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic or prognostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report

on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

NucleosomicsTM and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

Property of Volition© 2023

Slide 2

Who We Are

• Diagnostic company focusing on epigenetic markers
• • Epigenetics = on top of, or in addition to [the genome]
• Human and Veterinary use cases:
• • Screening
  • Monitoring (disease progression and response to treatment)
• We believe our addressable markets are significant $ 70 billion TAM1.
• Two key product areas anticipated in the short term (2023-2024):
• • Vet / Cancer, then NETosis (infections)
  • Human / NETosis

• Q4 '22 started to monetize our IP - Several global supply agreements

signed

1. VNRX TAM Model

Property of Volition© 2023

Slide 3

What sets us apart?

Key Differentiators:

• our Intellectual Property
• • Our patent portfolio is growing¹
  • Our products are protected until at least 2031 including animal diagnostics
  • Further breakthrough patents ongoing
• Our tests are simple, low-cost

ACCESSIBLE routine blood tests

1. IP as of 26th January 2023

122
patents
pending
worldwide1.	35 patent
	families
70 additional	(plus 3 in-licensed)1.
patents granted
worldwide in
growing IP
portfolio1.

	15 patents
12 patents	granted in
Europe1.
granted in
the U.S.1.

Property of Volition© 2023

Slide 4

What sets us apart?

Powered By

Property of Volition© 2023

Slide 5